← Leaderboards
Mingye Feng
Beckman Research Institute/City Of Hope
$6,090,660
Attributed
$6,441,907
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,441,907 · 6
By mechanism
R01$4,890,416 · 3
R00$746,912 · 1
R21$457,683 · 1
K99$346,896 · 1
Top collaborators
- Wendong Huang1 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Vu Nguyen Ngo$2,153,609
- Alexey V. Danilov$3,278,847
- Christiane Querfeld$3,066,660
- Jianhua Yu$11,234,533
- Behnam Badie$11,237,051
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularPhagocytosisIn VivoMediatingTumorMacrophageMalignant NeoplasmsImmunotherapyNatural Killer CellsB-LymphocytesSignal TransductionCancer CellSolid NeoplasmNeoplastic CellT-LymphocyteEatingCellsCancer TherapyExcisionMalignant - DescriptorIn VitroCd47 GenePhagocytesImmune
Grant awards (17)
Targeting Tumor-Associated Macrophages to Treat Lymphoma$702,495
R01 · FY2025 · CA
Targeting tumor-associated macrophages for triple-negative breast cancer treatment$519,592
R01 · FY2025 · CA · contact PI
Identifying and engaging a universal adjuvant for breaking macrophage immune tolerance in cancer$431,501
R01 · FY2025 · CA · contact PI
Non-receptor protein tyrosine phosphatases in macrophage-mediated cancer cell phagocytosis.$249,645
R21 · FY2025 · CA · contact PI
Targeting tumor-associated macrophages for triple-negative breast cancer treatment$493,611
R01 · FY2024 · CA · contact PI
Identifying and engaging a universal adjuvant for breaking macrophage immune tolerance in cancer$409,926
R01 · FY2024 · CA · contact PI
Non-receptor protein tyrosine phosphatases in macrophage-mediated cancer cell phagocytosis.$208,038
R21 · FY2024 · CA · contact PI
Targeting tumor-associated macrophages for triple-negative breast cancer treatment$509,199
R01 · FY2023 · CA · contact PI
Identifying and engaging a universal adjuvant for breaking macrophage immune tolerance in cancer$422,872
R01 · FY2023 · CA · contact PI
Targeting tumor-associated macrophages for triple-negative breast cancer treatment$538,218
R01 · FY2022 · CA · contact PI
Identifying and engaging a universal adjuvant for breaking macrophage immune tolerance in cancer$431,501
R01 · FY2022 · CA · contact PI
Identifying and engaging a universal adjuvant for breaking macrophage immune tolerance in cancer$431,501
R01 · FY2021 · CA · contact PI
MACROPHAGE-MEDIATED IMMUNOSURVEILLANCE IN CANCER$249,000
R00 · FY2019 · CA · contact PI
MACROPHAGE-MEDIATED IMMUNOSURVEILLANCE IN CANCER$248,912
R00 · FY2018 · CA · contact PI
MACROPHAGE-MEDIATED IMMUNOSURVEILLANCE IN CANCER$249,000
R00 · FY2017 · CA · contact PI
Macrophage-mediated Immunosurveillance in Cancer$173,448
K99 · FY2016 · CA · contact PI
Macrophage-mediated Immunosurveillance in Cancer$173,448
K99 · FY2015 · CA · contact PI